BCAB
Bioatla IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.12M
P/E Ratio
—
EPS
$-50.50
Beta
1.21
52W High
$71.50
52W Low
$3.92
50-Day MA
$7.30
200-Day MA
$23.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bioatla Inc
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $2.00M |
| Gross Profit (TTM) | $-41.07M |
| EBITDA | $-58.33M |
| Operating Margin | -462.80% |
| Return on Equity | -814.00% |
| Return on Assets | -110.80% |
| Revenue/Share (TTM) | $1.70 |
| Book Value | $-28.51 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 3.56 |
| EV/Revenue | 3.277 |
| EV/EBITDA | 0.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 31.60% |
| Shares Outstanding | $1.66M |
| Float | $1.38M |
| % Insiders | 5.63% |
| % Institutions | 19.51% |
Historical Volatility
HV 10-Day
157.81%
HV 20-Day
147.50%
HV 30-Day
139.53%
HV 60-Day
144.87%
HV Rank
—
Volatility is currently expanding
Data last updated: 4/29/2026